How to Get Rezdiffra (Resmetirom) in Missouri

What Is Rezdiffra and Why Does It Matter for Missouri Patients?

Rezdiffra (resmetirom) is the first FDA-approved oral medication specifically targeting MASH with liver fibrosis. The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH phase 3 trial, which enrolled 966 patients with biopsy-confirmed NASH and fibrosis stages F1B through F3 [1]. Before this approval, no pharmacotherapy existed for MASH. Patients relied on lifestyle changes alone.

In MAESTRO-NASH, 25.9% of patients receiving resmetirom 100 mg achieved NASH resolution with no worsening of fibrosis at 52 weeks, compared to 9.7% in the placebo group (P<0.001) [1]. The 80 mg dose also outperformed placebo, with 25.9% achieving at least one stage of fibrosis improvement versus 14.2% on placebo [1]. These biopsy-confirmed endpoints represent a measurable advance for the estimated 6 million to 8 million Americans living with at-risk MASH, according to the American Association for the Study of Liver Diseases [2].

Missouri has roughly 150,000 adults with MASH-related fibrosis, extrapolated from national prevalence data published by the National Institute of Diabetes and Digestive and Kidney Diseases [3]. For these patients, knowing how to access Rezdiffra through the state's prescribing, pharmacy, and insurance systems is the first step toward treatment.

Step-by-Step: Getting a Rezdiffra Prescription in Missouri

Start with a hepatologist, gastroenterologist, or primary care physician who has evaluated your liver disease staging. Rezdiffra is prescription-only, and prescribers need documented evidence of MASH with fibrosis (typically F2 or F3) before writing an order. Missouri law permits MDs, DOs, nurse practitioners operating under a collaborative practice agreement, and physician assistants to prescribe resmetirom per the FDA label [4].

The prescription process generally follows this sequence:

1. Diagnostic workup. Your clinician orders liver function tests (ALT, AST, GGT, albumin, bilirubin, platelet count), a FIB-4 index calculation, and often a FibroScan or MR elastography to stage fibrosis non-invasively.
2. Biopsy confirmation (if needed). Some insurers require liver biopsy documentation showing NASH Activity Score (NAS) of 4 or higher and fibrosis stage F2-F3. Others accept validated non-invasive scores.
3. Prescription submission. The prescriber sends the order to a specialty pharmacy or 503A compounding pharmacy licensed in Missouri.
4. Prior authorization. Most commercial plans require PA. Your prescriber's office submits clinical documentation, lab results, and imaging reports.

Expect the entire process to take 7 to 21 days from initial prescription to dispensing, depending on insurer response times. Some specialty pharmacies offer bridge programs to accelerate first fills.

Telehealth Access to Rezdiffra in Missouri

Missouri fully permits telehealth prescribing of resmetirom, and several hepatology-focused telehealth platforms now serve the state. A Missouri-licensed prescriber can evaluate you via video visit, review uploaded labs and imaging, and transmit an electronic prescription to a Missouri pharmacy. This is legal. The Missouri Board of Registration for the Healing Arts authorizes telemedicine prescribing when a valid provider-patient relationship has been established [5].

Telehealth works best for patients who already have a MASH diagnosis and documented fibrosis staging. If you need baseline labs or imaging, you will still visit a local lab (Quest, Labcorp, or a hospital outpatient lab). Your telehealth provider can order these remotely and review results during a follow-up video appointment.

One practical advantage of telehealth: faster prior authorization turnaround. Telehealth-native practices often have dedicated PA teams that submit documentation within 24 to 48 hours of the initial visit, compared to 5 to 10 business days at some brick-and-mortar hepatology offices. For Missouri patients in rural areas where the nearest hepatologist may be 90 minutes away in Kansas City or St. Louis, telehealth removes a significant geographic barrier.

The American Telemedicine Association has documented that telehealth increases specialty medication access in rural states by 30 to 40% for chronic conditions requiring specialist prescribing [6].

Required Labs Before Starting Rezdiffra in Missouri

Your prescriber will order a specific panel before initiating resmetirom. This is not optional. The FDA prescribing information mandates liver function monitoring, and insurers require baseline results for prior authorization [4].

Baseline labs required:

• Complete metabolic panel (CMP): includes ALT, AST, alkaline phosphatase, bilirubin, albumin, and creatinine
• CBC with platelets: needed for FIB-4 calculation
• Lipid panel: resmetirom acts as a thyroid hormone receptor-beta (THR-beta) agonist and reduces LDL cholesterol; baseline lipids establish treatment response
• Thyroid function tests (TSH, free T4): required to rule out thyroid dysfunction before starting a THR-beta agonist
• FIB-4 score: calculated from age, AST, ALT, and platelet count; scores above 1.3 suggest significant fibrosis

Imaging often required:

• FibroScan (vibration-controlled transient elastography): available at most Missouri hepatology centers in St. Louis, Kansas City, Springfield, and Columbia
• MR elastography: available at academic medical centers including Washington University in St. Louis and University of Missouri Health Care

The AASLD practice guidance on NAFLD/MASH recommends non-invasive testing as the initial fibrosis assessment, reserving liver biopsy for cases where non-invasive results are indeterminate [2]. Some commercial insurers still require biopsy documentation. Check your plan's specific PA criteria.

Prior Authorization in Missouri: What You Need

Most commercial insurers and Missouri's managed Medicaid plans require prior authorization for Rezdiffra. Missouri Medicaid (MO HealthNet) does not currently cover resmetirom for MASH; coverage is limited to type 2 diabetes indications under existing formulary rules. Patients on MO HealthNet may need to pursue manufacturer assistance or appeal through the Missouri Department of Social Services [7].

For commercial plans, PA documentation typically includes:

• Diagnosis codes: K75.81 (MASH/NASH) with a fibrosis stage modifier
• Lab results: baseline CMP, CBC, lipid panel, TSH within the past 90 days
• Fibrosis staging: FibroScan result, MRE result, or liver biopsy report confirming stage F2 or F3
• Prior treatment history: documentation that lifestyle modifications (diet, exercise, weight management) were attempted
• Prescriber specialty: some plans require the prescriber to be a hepatologist or gastroenterologist, though this is not universal

The 2023 AACE Clinical Practice Guideline for NAFLD recommends pharmacotherapy for patients with NASH and significant fibrosis (F2 or higher) who have not responded adequately to lifestyle intervention [8]. Citing this guideline in your PA submission strengthens the medical necessity argument.

PA decisions typically arrive within 5 to 15 business days. If denied, you have the right to a peer-to-peer review, where your prescriber speaks directly with the insurer's medical director. Denial overturn rates for specialty hepatology drugs run between 40% and 60% after peer-to-peer, based on data from the American Gastroenterological Association [9].

Pharmacy Options in Missouri

Once your prescription clears PA, you have two main pharmacy pathways in Missouri.

Specialty pharmacies handle the majority of Rezdiffra prescriptions nationally. These pharmacies carry the branded product from Madrigal Pharmaceuticals and typically ship directly to your home. Major specialty pharmacy networks serving Missouri include CVS Specialty, Accredo (Express Scripts), and AllianceRx Walgreens Prime. Turnaround from PA approval to doorstep delivery is usually 3 to 5 business days.

503A compounding pharmacies in Missouri hold valid state licenses and may compound resmetirom for individual patient prescriptions. Missouri's Board of Pharmacy regulates 503A facilities under state law consistent with FDA guidance on 503A compounding [10]. A 503A pharmacy compounds medications based on a patient-specific prescription, which may offer cost advantages for uninsured or underinsured patients. Confirm that the pharmacy sources pharmaceutical-grade resmetirom active ingredient and operates under current Good Manufacturing Practice (cGMP) standards.

Patients should verify that their chosen pharmacy is licensed with the Missouri Board of Pharmacy and has experience dispensing hepatology specialty medications. Ask whether the pharmacy offers copay assistance enrollment, since Madrigal Pharmaceuticals maintains a patient support program (Rezdiffra Connect) that may reduce out-of-pocket costs for commercially insured patients.

Cost and Financial Assistance

Rezdiffra's wholesale acquisition cost is approximately $47,400 per year at the 100 mg daily dose. Out-of-pocket costs vary dramatically by insurance type.

Commercially insured patients with PA approval typically pay $0 to $150 per month through the Madrigal copay assistance program. Patients without commercial insurance face the full cost unless they qualify for the Madrigal Patient Assistance Program, which provides free drug to eligible uninsured patients with household income below 400% of the federal poverty level.

Missouri Medicaid patients face the most difficult access path. MO HealthNet does not list resmetirom on its preferred drug list for MASH. Patients on Medicaid can file a non-formulary exception request through their managed care organization, but approval rates remain low in early 2026. The Centers for Medicare & Medicaid Services allows state Medicaid programs discretion on coverage of accelerated-approval drugs [11].

Medicare Part D plans vary. Some have added resmetirom to specialty tiers with 25% to 33% coinsurance after the deductible. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully effective in 2025, limits exposure for Medicare beneficiaries regardless of tier placement [11].

Monitoring After Starting Rezdiffra

Once you begin taking resmetirom, expect regular follow-up. The FDA label recommends checking liver function tests (ALT, AST, bilirubin) periodically during treatment [4]. Most prescribers order labs at 4 weeks, 12 weeks, and every 3 to 6 months thereafter.

Lipid monitoring matters too. Resmetirom reduces LDL cholesterol by approximately 14% to 22% as a secondary pharmacologic effect, based on MAESTRO-NASH data [1]. If you take a statin, your prescriber may adjust the dose downward. Watch for over-reduction of LDL below 40 mg/dL, which warrants clinical reassessment.

Report any of these symptoms promptly: new or worsening nausea (occurred in 26.2% of the 100 mg group vs. 18.2% placebo in MAESTRO-NASH), diarrhea (33.0% vs. 19.1%), or abdominal pain [1]. Most gastrointestinal side effects resolve within the first 4 to 12 weeks of treatment.

The AASLD recommends repeat non-invasive fibrosis assessment (FibroScan or MRE) at 12 months to gauge treatment response [2]. Continued worsening of fibrosis markers despite adherence may prompt your prescriber to reconsider the treatment plan.

Transferring a Prescription to Missouri

If you hold a valid resmetirom prescription from another state, Missouri permits prescription transfers. Your current pharmacy can transfer the prescription electronically to a Missouri-licensed pharmacy. Missouri does not require a new in-state prescriber visit for transferred prescriptions, though your new pharmacy will verify the prescription's validity and may contact the original prescriber.

For patients relocating to Missouri, establishing care with a Missouri-licensed hepatologist or gastroenterologist within 90 days of the transfer is recommended. This ensures continuity of monitoring labs and follow-up imaging. Telehealth appointments with a Missouri-licensed provider can bridge the gap if wait times for in-person hepatology consultations run long, as they often do at academic centers in St. Louis and Kansas City.